Heart surgery patients may need fewer transfusions with EPO and iron combo
NCT ID NCT04141631
First seen Jun 24, 2026 · Last updated Jun 24, 2026
Summary
This study tested whether giving erythropoietin (EPO) and an iron injection before heart surgery could lower the number of patients needing blood transfusions. 128 adults scheduled for heart surgery who were at high risk of transfusion took part. The approach aimed to boost hemoglobin levels and guide transfusions using a measure of oxygen in the blood.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CARDIAC SURGERY are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
DEpartement d'anesthésie et réanimation D - Arnaud de Villeneuve
Montpellier, 34295, France
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
erythropoietin (EPO) and ferric carboxymaltose (iron injection)
What this could lead to
If successful, this approach could reduce the need for blood transfusions in heart surgery patients, lowering risks and costs.
What could go wrong
This is a completed study with 128 patients, so results are limited. The strategy may not work for all patients or settings, and there are risks like allergic reactions to the drugs.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.